ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VEC Vectura Group Plc

164.80
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group Plc LSE:VEC London Ordinary Share GB00BKM2MW97 ORD 0.0271P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 164.80 164.80 165.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Vectura Share Discussion Threads

Showing 4601 to 4623 of 12050 messages
Chat Pages: Latest  194  193  192  191  190  189  188  187  186  185  184  183  Older
DateSubjectAuthorDiscuss
06/8/2016
16:51
Vec will buy them out...lol
richtea1701
06/8/2016
16:32
Thanks Car !Let's hope Vec has something up its sleeve to counter the Norvartis 'threat' else in few years bottom line will not look so healthy
ropey
06/8/2016
15:44
Great news for asthma sufferers, potentially, but must be of concern to Vectura's future direction. They'll be well aware of its existence of course, rather ironic that it's developed by Novartis. A few years and phases away maybe but this new pill could threaten inhaler market stability and lessen the attractiveness that others might have found in Vectura's products.
carpadium
06/8/2016
14:26
Does VEC have anything to do with te development of Fevipiprant or would this be a big competitor to VEC...?...in which case share price will tank on Monday !!...imho off course !
ropey
06/8/2016
00:23
Wondering how this might impact the respiratory pharma industry... https://www.google.co.uk/amp/s/amp.theguardian.com/society/2016/aug/06/fevipiprant-asthma-drug-trial-treatment
saxula
05/8/2016
15:49
I asked Mundipharma when the COPD trial results would be published.The reply came from Nappa Pharmaceuticals in Cambridge. It turns out they are an associate company of Mundipharma and carry out trials.Their only comment was that they don't yet have a date for publication- not surprising since it would be market sensitive, but it was worth a try!
fhmktg
05/8/2016
07:47
fhmktg - yes, that's going to be the big news of the year. I'm surprised the results aren't out by now but it's Mundipharma's trial so it is up to them to announce the results. Perhaps that's why Vec are reluctant to say when.
alexchry
05/8/2016
07:40
Alex, yea you're right, should have checked it out...
diesel
05/8/2016
07:39
Now....where is that COPD trial report!I have asked the company for an expected timetable, but no reply, which I take to mean 'anytime soon'
fhmktg
05/8/2016
07:32
Vectura press release is wrong, it should say 'EXPAREL net product sales were $65.8 million in the second quarter of 2016, a 15% increase over the $57.0 million reported for the second quarter of 2015'.
alexchry
05/8/2016
07:28
Am new to VEC however have been through the numbers and a basic merger model with SKP. Based on the forecasts for FY16 for SKP pre-acquisition and a bit of growth for VEC, it looks like market forecasts of 6.45p are a good bit short. Does anyone come to the same conclusion?
Thanks

adamb1978
05/8/2016
07:20
Boa...think that should read 2016! So the total income from Pacira alone has probably gone up £1m since brexit and the currency change, strange why the share price here has responded so badly of late.
diesel
05/8/2016
07:18
Welcome news but the numbers are already in the forecast for the year. I'm hoping for some unexpected good news to properly reverse the slide down from over 170.
alexchry
05/8/2016
07:10
Some news which might give us a tick up at last!

I hope it's a milestone rather than a millstone otherwise we might get a tick down! (see 4499)

Also the stated 15% comparative is strange. A normal comparative would be either the preceding quarter (1Q2016) or corresponding quarter of previous year (2Q2015). Not sure whether to suspect a misprint.

On $250+m @3%, that is also a further $7.5+m over the year.

boadicea
05/8/2016
06:25
Turning out to be a nice little earner.Dental sales could be substantial if it shows lasting benefits over lidocaine!
fhmktg
05/8/2016
06:22
That might cheer us up
richtea1701
04/8/2016
20:19
Pacira results out 250million dollar sales millstone triggered ,so 8 million millstone payment
best1467
03/8/2016
20:57
Vec is certainly a laggard. Keeping the faith though
richtea1701
01/8/2016
11:40
We do seem to be going only one way at the moment DOWN !!!!!!!
pooroldboy55
29/7/2016
10:01
Short term pain is always good medicine Boad
richtea1701
29/7/2016
09:14
Well the licence news certainly caused a volume spike but not much damage to the share price and today it's reversing the fall. Perhaps shorters are covering or some dumpers having second thoughts. It could actually leave it stronger overall within a few days with loose holders shaken out. (I hesitate to suggest that could have been a deliberate ploy!)

The share price was already in a relatively lowly position that seemed to discount the possibility of some bad news in an otherwise bright outlook. Those who took fright yesterday may have to pay dearly for the privilege of returning if good trials news breaks soon.

boadicea
29/7/2016
08:06
Agree - I felt at the time a sense of relief that is was not a failed trial that was the insider line and the weakness. Hopefully now some confidence can return.
richtea1701
29/7/2016
07:39
I am pleased that the bad news is concerned with patents/licensing as I thought it might be bad news about the COPD trial. The result of this trial will be the most significant event this year. The trial started in Sept 2013 and was due to complete in May this year with data collection being completed the month before. The 52 week trial was being conducted in many countries around the world, it must have cost Mundipharma a pretty penny. A successful result will significantly expand the market for Flutiform. I did spend a long time waiting for Flutiform to be approved in the USA, my hopes and my finances were dashed then, I'm hoping for better news this time.
alexchry
Chat Pages: Latest  194  193  192  191  190  189  188  187  186  185  184  183  Older

Your Recent History

Delayed Upgrade Clock